Collaborative Bioprocessing: Next-Gen mAb Downstream Manufacturing Enhanced By Transcenta Partnership

The bioprocessing industry faces an urgent need to intensify downstream operations and make them more efficient, compact, and cost-effective. Although various technologies and methods are available to enhance individual unit operations, employing them in an integrated, next-generation bioprocess remains a significant challenge. Through a collaboration between MilliporeSigma and Transcenta, an advanced, highly automated bioprocessing train designed for the production of monoclonal antibodies and other biologics has been successfully developed.

In this webinar, you will learn about the bioprocessing template, operational paradigm, and the intricacies of qualifying this state-of-the-art manufacturing approach.